Results from the AnteNOR project: Norway’s way towards precision prevention

/in , /by

Event Details

Welcome to this hybrid seminar marking the end of the AnteNOR project.

The AnteNOR project explores how to improve prevention and early detection of breast cancer in Norway. The project focuses on polygenic risk-score tests, a new type of technology that can provide a measure of someone’s personal risk to develop a disease.

During this seminar, we will address the research and clinical results of the project. We will also present a new relevant EU call on accessible and affordable genetic or genomic risk predictor tests to advance early cancer detection in European regions. Finally, there will be a panel discussion about home tests and cancer screening next steps in Norway. The discussion will address various topics, including the implementation of such tests, follow-up care, policy aspects, or co-creation with users. 

Programme

13:00-13:50 AnteNOR project: research results and precision breast cancer implementation policy

  • Conclusions from the AnteNOR project – opening the way for the implementation of breast cancer precision prevention, by Peeter Padrik, Oncologist and CEO, Antegenes
  • Performance of a breast cancer polygenic risk score in a Norwegian population, by Eivind Hovig, Professor at the Centre for Bioinformatics at the University of Oslo, and group leader at the Institute for Cancer Research, Oslo University Hospital
  • Clinical pilot study using polygenetic risk score and patient feedback, by Tone Hovda, senior radiologist, Vestre Viken Hospital Trust

13:50-14:05 Presentation of Cancer Mission call: “Accessible and affordable tests to advance early detection of heritable cancers in European regions”. Presented by Sofia Anderholm Strand, Senior Advisor at the Research Council of Norway.

14:05-14:30 Break & informal discussions

14:30-15:00 Panel discussion around home testing and cancer screening next steps. Participants are:

  • Bo Terning Hansen, Senior Researcher at FHI
  • Sara Underland Mjelva, Leader of the section for prevention at the Norwegian Cancer Society
  • Peeter Padrik, oncologist and CEO of Antegenes, representative of the AnteNOR project
  • Karl-Arne Johannessen, representing the company Tigeni
  • Ketil Widerberg, General Manager of Oslo Cancer Cluster, will moderate the discussion

On-site and digital

The seminar is free to attend and open to all. Please sign up at the bottom of this page. The digital audience will receive the streaming link one day before the seminar. 

The Norway Grants Green ICT programme has kindly supported the AnteNOR project.

AnteNOR has the following partners: OÜ Antegenes, Oslo Cancer Cluster, Oslo Universitetsykehus, Oslo University and Vestre Viken Hospital Trust.

 

Please see the AnteNOR project page for more information.